{"id":1527,"date":"2020-07-11T16:53:38","date_gmt":"2020-07-11T14:53:38","guid":{"rendered":"http:\/\/invivo.partners\/portoflio_invivo\/onechain-immunotherapeutics\/"},"modified":"2024-03-05T12:23:12","modified_gmt":"2024-03-05T11:23:12","slug":"onechain-immunotherapeutics","status":"publish","type":"portoflio_invivo","link":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/","title":{"rendered":"OneChain Immunotherapeutics"},"content":{"rendered":"\r\n<p class=\"wp-block-paragraph\">OneChain Immunotherapeutics \u00e9s una empresa <em>spin-off<\/em> de l&#8217; <strong>Institut de Recerca contra la Leuc\u00e8mia Josep Carreras<\/strong> (IJC) i <strong>ICREA<\/strong>. L&#8217;objectiu de l&#8217;empresa \u00e9s desenvolupar inmunoter\u00e0pies contra les neopl\u00e0sies hematol\u00f2giques utilitzant <strong>ter\u00e0pies amb c\u00e8l\u00b7lules T Gamma Delta<\/strong> i generar nous candidats <strong>CAR-T<\/strong> contra diferents ant\u00edgens. El primer candidat \u00e9s un CAR-CD1a per a la co-T-ALL. L&#8217;objectiu de l&#8217;empresa \u00e9s desenvolupar ter\u00e0pies CAR-T utilitzant una <strong>plataforma al\u00b7log\u00e8nica<\/strong> basada en un m\u00e8tode nou i eficient per a la generaci\u00f3 selectiva de <strong>c\u00e8l\u00b7lules V\u03b41 + T<\/strong> citot\u00f2xiques humanes.<\/p>\r\n\r\n\r\n\r\n<ul class=\"wp-block-list\">\r\n<li>CEO: Stefanos Theoharis<\/li>\r\n<li>CSO i Fundador: Pablo Men\u00e9ndez<\/li>\r\n<li>Ubicaci\u00f3: Barcelona<\/li>\r\n<li>P\u00e0gina web: <a href=\"http:\/\/onechaintx.com\" target=\"_blank\" rel=\"noreferrer noopener\">onechaintx.com<\/a><\/li>\r\n<\/ul>\r\n","protected":false},"featured_media":0,"template":"","tipo_portfolio":[507],"class_list":["post-1527","portoflio_invivo","type-portoflio_invivo","status-publish","hentry","tipo_portfolio-invivoventures"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>OneChain Immunotherapeutics - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OneChain Immunotherapeutics - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"OneChain Immunotherapeutics \u00e9s una empresa spin-off de l&#8217; Institut de Recerca contra la Leuc\u00e8mia Josep Carreras (IJC) i ICREA. L&#8217;objectiu de l&#8217;empresa \u00e9s desenvolupar inmunoter\u00e0pies contra les neopl\u00e0sies hematol\u00f2giques utilitzant ter\u00e0pies amb c\u00e8l\u00b7lules T Gamma Delta i generar nous candidats CAR-T contra diferents ant\u00edgens. El primer candidat \u00e9s un CAR-CD1a per a la co-T-ALL. L&#8217;objectiu\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-05T11:23:12+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/\",\"url\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/\",\"name\":\"OneChain Immunotherapeutics - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2020-07-11T14:53:38+00:00\",\"dateModified\":\"2024-03-05T11:23:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OneChain Immunotherapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OneChain Immunotherapeutics - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/","og_locale":"ca_ES","og_type":"article","og_title":"OneChain Immunotherapeutics - Invivo Partners","og_description":"OneChain Immunotherapeutics \u00e9s una empresa spin-off de l&#8217; Institut de Recerca contra la Leuc\u00e8mia Josep Carreras (IJC) i ICREA. L&#8217;objectiu de l&#8217;empresa \u00e9s desenvolupar inmunoter\u00e0pies contra les neopl\u00e0sies hematol\u00f2giques utilitzant ter\u00e0pies amb c\u00e8l\u00b7lules T Gamma Delta i generar nous candidats CAR-T contra diferents ant\u00edgens. El primer candidat \u00e9s un CAR-CD1a per a la co-T-ALL. L&#8217;objectiu","og_url":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/","og_site_name":"Invivo Partners","article_modified_time":"2024-03-05T11:23:12+00:00","twitter_card":"summary_large_image","twitter_misc":{"Temps estimat de lectura":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/","url":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/","name":"OneChain Immunotherapeutics - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2020-07-11T14:53:38+00:00","dateModified":"2024-03-05T11:23:12+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/ca\/portoflio_invivo\/onechain-immunotherapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/ca\/"},{"@type":"ListItem","position":2,"name":"OneChain Immunotherapeutics"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/portoflio_invivo\/1527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/portoflio_invivo"}],"about":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/types\/portoflio_invivo"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/media?parent=1527"}],"wp:term":[{"taxonomy":"tipo_portfolio","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/tipo_portfolio?post=1527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}